In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Synercid (quinupristin/dalfopristin, RP59500) is a new water-soluble streptogramin which offers some advantages over the commercially available antimicrobials against drug-resistant gram-positive bacteria. Its in vitro activity was compared with ampicillin, augmentin, penicillin, erythromycin, oxacillin and vancomycin against gram-positive bacteria isolated from clinical specimens. Of the 837 gram-positive bacteria tested 834 (99.6%) were inhibited by < 0.6-4.0 mg/l of Synercid. It had excellent activity against both staphylococci and streptococci, including methicillin-resistant staphylococci and vancomycin-resistant enterococci.
Qadri
S M
SM
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Ueno
Y
Y
Abu Mostafa
F M
FM
Halim
M
M
D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects; D004917:Erythromycin / Q000494:pharmacology; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D004917:Erythromycin; D014640:Vancomycin; D000667:Ampicillin; D010068:Oxacillin